NCT04711603

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 178 (actual)
• Sponsor: Kissei Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and followed by extension, open-label treatment to confirm long-term safety of MA13A9 in hemodialysis patients with pruritus.

Conditions

• Uremic Pruritus

Interventions

Type	Name	Description
DRUG	MR13A9	Intravenous administration
DRUG	Placebo	Intravenous administration

Timeline

• Start date: 2021-01-16
• Primary completion: 2022-01-25
• Completion: 2022-09-26
• First posted: 2021-01-15
• Last updated: 2025-09-10
• Results posted: 2025-09-10

Locations

1 site across 1 country: Japan